A397030 Stock Overview
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AprilBio Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩19,550.00 |
| 52 Week High | ₩22,350.00 |
| 52 Week Low | ₩9,385.00 |
| Beta | 0 |
| 11 Month Change | 0.26% |
| 3 Month Change | 27.03% |
| 1 Year Change | 83.14% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 78.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| A397030 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.4% | -0.3% | -3.7% |
| 1Y | 83.1% | 29.5% | 2.4% |
Return vs Industry: A397030 exceeded the KR Biotechs industry which returned 29.5% over the past year.
Return vs Market: A397030 exceeded the KR Market which returned 2.4% over the past year.
Price Volatility
| A397030 volatility | |
|---|---|
| A397030 Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A397030's share price has been volatile over the past 3 months.
Volatility Over Time: A397030's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Sang-Hoon Cha | www.aprilbio.com |
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops products based on its long-acting protein medicine platform technology. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases.
AprilBio Co.,Ltd. Fundamentals Summary
| A397030 fundamental statistics | |
|---|---|
| Market cap | ₩424.66b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A397030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A397030 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A397030 perform over the long term?
See historical performance and comparison